TECH vs RVTY vs A Stock Comparison

Bio-Techne, Revvity and Agilent Technologies Prices as of Oct 23, 2026 Peers: Industry group
1 more company in this comparison (TWST) Create a free account to keep reading and compare up to 10 companies.
TECH BIO-TECHNE Corp
$72.55 +0.0% 1M +9.8% 1Y
Market cap
$11.34B
P/E
62.3x
Revenue (TTM)
$1.22B
Div. yield
0.00%
Life Sciences Tools Healthcare
2 wins
RVTY Revvity, Inc.
$158.70 +11.7% 1M +62.7% 1Y
Market cap
$17.90B
P/E
75.4x
Revenue (TTM)
$2.91B
Div. yield
0.00%
Life Sciences Tools Healthcare
1 win
A Agilent Technologies, Inc.
$173.05 +4.7% 1M +17.4% 1Y
Market cap
$49.59B
P/E
34.4x
Revenue (TTM)
$7.37B
Div. yield
0.01%
Life Sciences Tools Healthcare
9 wins

Head to Head

12 decided of 12

Agilent Technologies leads on 9 of the 12 questions below (Agilent Technologies 9, Bio-Techne 2, Revvity 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionTECHRVTYALeader
Larger companyMarket capitalisation $11.34B $17.90B $49.59B A
Cheaper on earningsLower P/E, profitable companies only 62.3x 75.4x 34.4x A
Cheaper on forward earningsLower price / next fiscal year consensus EPS 33.6x 31.1x 26.5x A
Faster revenue growthRevenue growth, trailing twelve months -0.4% +4.1% +8.6% A
More profitableNet margin, trailing twelve months 15.0% 8.2% 19.5% A
Better return on capitalReturn on invested capital 8.3% 3.1% 13.1% A
Less leveragedLower net debt / EBITDA -0.2x 2.8x 1.1x TECH
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.01% A
Better 1-year returnPrice return, last 12 months +9.8% +62.7% +17.4% RVTY
Better 5-year returnAnnualised price return, 5 years -10.5%/yr -2.1%/yr +1.8%/yr A
Less volatileAnnualised volatility, 1 year 43.6% 39.9% 32.3% A
Higher overall scoreMean of the five percentile scores vs peers 65/100 58/100 62/100 TECH

Percentile Scorecard

TECHRVTYA

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisTECHRVTYA
Valuation 57 #99 of 228 69 #72 of 228 57 #98 of 228
Growth 39 #137 of 222 27 #163 of 222 36 #143 of 222
Profitability 94 #14 of 210 79 #46 of 210 91 #20 of 210
Financial Health 86 #34 of 241 47 #128 of 241 55 #108 of 241
Shareholder Returns 49 #71 of 138 68 #45 of 138 69 #43 of 138
Overall 65 58 62
  • TECH ranked among 248 companies in Medical Devices and Diagnostics
  • RVTY ranked among 248 companies in Medical Devices and Diagnostics
  • A ranked among 248 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodTECHRVTYASPY
1 month +0.0%+11.7%+4.7% -1.0%
3 months +1.3%+43.7%+24.9% +2.9%
6 months +33.9%+82.9%+49.8% +6.4%
Year to date +23.4%+64.0%+27.2% +11.4%
1 year +9.8%+62.7%+17.4% +13.1%
3 years +14.0%+55.8%+63.8% +79.4%
3 years, per year +4.5%+15.9%+17.9% +21.5%
5 years -42.6%-10.0%+9.5% +67.7%
5 years, per year -10.5%-2.1%+1.8% +10.9%
10 years +176.5%+201.2%+279.7% +255.2%
10 years, per year +10.7%+11.7%+14.3% +13.5%

Risk

MeasureTECHRVTYASPY
Volatility, 1Y 43.6%39.9%32.3% 12.7%
Downside volatility, 1Y 43.4%35.7%27.5% 12.7%
Beta vs S&P 500, 1Y 0.751.200.86 1.00
Return / volatility, 1Y 0.231.570.54 1.03
Max drawdown, 5Y -67.0%-59.2%-39.6% -25.4%
From 52-week high -0.1%0.0%-2.6% -2.5%
52-week high $72.64$158.70$177.72 $779.14
52-week low $43.30$82.26$110.24 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleTECHRVTYA
P/E now vs peer median 62.2xmedian 30.7x 74.5xmedian 30.7x 33.9xmedian 30.7x
P/S now vs peer median 9.3xmedian 3.0x 6.1xmedian 3.0x 6.6xmedian 3.0x
EV/EBITDA now vs peer median 32.2xmedian 17.7x 25.6xmedian 17.7x 26.7xmedian 17.7x
P/FCF now vs peer median 43.0xmedian 23.7x 31.1xmedian 23.7x 38.5xmedian 23.7x
P/B now vs peer median 5.4xmedian 2.4x 2.4xmedian 2.4x 6.6xmedian 2.4x
PEG now vs peer median -4.77median 0.96 -2.39median 0.96 3.45median 0.96

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsTECHRVTYA
Revenue $1.22B $2.91B $7.37B
Gross profit $799.07M $1.60B $3.97B
Operating income $251.89M $358.85M $1.64B
Net income $181.86M $237.55M $1.44B
Free cash flow $263.22M $568.85M $1.27B
R&D $94.77M $215.83M $485.00M
EPS (diluted) $1.16 $2.13 $5.09
Cash & equivalents $264.71M $1.02B $1.76B
Total debt $960.00M $3.21B $3.95B
Shares (diluted) 157.01M 111.63M 283.00M
Enterprise value $10.54B $14.17B $42.48B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricTECHRVTYA
P/E 62.2x 74.5x 33.9x
P/FCF 43.0x 31.1x 38.5x
P/Operating cash flow 38.8x 27.7x 30.3x
P/S 9.3x 6.1x 6.6x
P/B 5.4x 2.4x 6.6x
P/Tangible book 6.3x 3.5x 7.6x
EV/EBITDA 32.2x 25.6x 26.7x
EV/EBIT 44.7x 55.4x 31.1x
EV/Revenue 9.3x 6.8x 6.9x
EV/FCF 42.8x 35.0x 40.2x
EV/Operating cash flow 38.6x 31.2x 31.7x
PEG (3Y EPS CAGR) -4.77 -2.39 3.45

Growth

14 metrics
MetricTECHRVTYA
Revenue growth (1Y) -0.4% 4.1% 8.6%
Revenue CAGR (3Y) 2.2% 0.9% 1.8%
Gross profit growth (1Y) 1.1% 2.3% 11.2%
Gross profit CAGR (3Y) 1.3% -0.4% 3.7%
Operating income growth (1Y) 146.3% -5.5% 13.5%
Operating income CAGR (3Y) -5.5% -3.7% 5.1%
Net income growth (1Y) 147.8% -16.7% 18.0%
Net income CAGR (3Y) -14.0% -33.8% 8.3%
EPS growth (1Y) 152.0% -12.3% 18.9%
EPS CAGR (3Y) -13.1% -31.2% 9.8%
Operating cash flow growth (1Y) 1.6% 6.2% 7.6%
Operating cash flow CAGR (3Y) 4.7% 86.9% -1.9%
Free cash flow growth (1Y) 2.6% 9.5% 16.5%
Free cash flow CAGR (3Y) 6.8% 64.8% -3.7%

Profitability

14 metrics
MetricTECHRVTYA
Gross margin 65.8% 55.0% 53.8%
EBITDA margin 28.7% 26.6% 25.9%
Operating margin 20.7% 12.3% 22.2%
Pretax margin 19.8% 9.0% 22.5%
Net margin 15.0% 8.2% 19.5%
FCF margin 21.7% 19.5% 17.2%
Operating cash flow margin 24.0% 21.9% 21.8%
Return on equity 8.7% 3.3% 19.9%
Return on assets 7.1% 2.0% 10.7%
Return on invested capital 8.3% 3.1% 13.1%
Return on capital employed 10.5% 3.3% 14.6%
Asset turnover 0.5x 0.2x 0.5x
Cash conversion (OCF / net income) 1.6x 2.7x 1.1x
Stock comp / revenue 0.5% 0.8% 1.8%

Financial Health

11 metrics
MetricTECHRVTYA
Debt / assets 7.7% 26.6% 28.3%
Debt / equity 0.1x 0.4x 0.5x
Net debt / EBITDA -0.2x 2.8x 1.1x
Debt / FCF 0.8x 5.6x 3.1x
Liabilities / assets 18.5% 40.0% 47.3%
Equity / assets 81.5% 60.0% 52.7%
Interest coverage 26.2x 3.7x 15.5x
Current ratio 4.5x 1.8x 2.1x
Quick ratio 2.9x 1.4x 1.4x
Cash ratio 1.6x 0.8x 0.8x
Altman Z-score 15.88 3.36 5.75

Shareholder Returns

7 metrics
MetricTECHRVTYA
Dividend yield 0.4% 0.2% 0.6%
Net buyback yield -0.3% 2.6% 0.6%
Shareholder yield 0.1% 2.8% 1.2%
Payout ratio (earnings) 27.4% 13.4% 19.9%
Payout ratio (FCF) 19.0% 5.6% 22.6%
Dividend growth (1Y) -0.9% -6.3% 2.1%
Dividend CAGR (3Y) -0.2% -6.1% 3.1%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusTECHRVTYA
Forward P/E 33.6xFY2027 31.1xFY2026 26.5xFY2026
EPS, next fiscal year $2.16FY2027 $5.10FY2026 $6.54FY2026
EPS growth, next FY +11.9%FY2027 +0.8%FY2026 +17.0%FY2026
EPS growth, the year after +5.1% +11.0% +0.6%
Revenue, next fiscal year $1.19BFY2027 $2.98BFY2026 $7.87BFY2026
Revenue growth, next FY -2.1%FY2027 +4.0%FY2026 +15.3%FY2026
Revenue growth, the year after +13.5% -2.0% -5.6%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersTECHRVTYA
Held by institutions 100.0% 100.0% 92.6%
Institutions holding 597 545 1,122
Change in shares held, QoQ -0.6% -1.3% +3.2%
Institutions buying 293 301 599
Institutions selling 241 161 350
Buyers to sellers 1.22 1.87 1.71

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

TECHRVTYA
TECH 1.00 0.45 0.48
RVTY 0.45 1.00 0.64
A 0.48 0.64 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, TECH, RVTY and A?

Agilent Technologies (A) is the largest by market capitalisation: Bio-Techne (TECH) $11.34B, Revvity (RVTY) $17.90B, Agilent Technologies (A) $49.59B.

Which stock is cheaper, TECH, RVTY and A?

Agilent Technologies (A) trades on the lowest price-to-earnings ratio (Bio-Techne (TECH) 62.3x, Revvity (RVTY) 75.4x, Agilent Technologies (A) 34.4x). On next year's consensus earnings, Agilent Technologies (A) is cheapest (Bio-Techne (TECH) 33.6x, Revvity (RVTY) 31.1x, Agilent Technologies (A) 26.5x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Agilent Technologies (A) grew revenue fastest over the trailing twelve months: Bio-Techne (TECH) -0.4%, Revvity (RVTY) +4.1%, Agilent Technologies (A) +8.6%.

Which company is more profitable?

Agilent Technologies (A) has the highest net margin (Bio-Techne (TECH) 15.0%, Revvity (RVTY) 8.2%, Agilent Technologies (A) 19.5%). On return on invested capital, Agilent Technologies (A) leads (Bio-Techne (TECH) 8.3%, Revvity (RVTY) 3.1%, Agilent Technologies (A) 13.1%).

Which stock has performed better?

Over the past year Revvity (RVTY) returned the most: Bio-Techne (TECH) +9.8%, Revvity (RVTY) +62.7%, Agilent Technologies (A) +17.4%. Over five years, Agilent Technologies (A) compounded fastest (Bio-Techne (TECH) -10.5%/yr, Revvity (RVTY) -2.1%/yr, Agilent Technologies (A) +1.8%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Agilent Technologies (A) has the highest dividend yield: Bio-Techne (TECH) 0.00%, Revvity (RVTY) 0.00%, Agilent Technologies (A) 0.01%.

Which stock is riskier?

By one-year price volatility, Agilent Technologies (A) has been the steadiest (Bio-Techne (TECH) 43.6%, Revvity (RVTY) 39.9%, Agilent Technologies (A) 32.3%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, TECH, RVTY and A?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Agilent Technologies (A) leads on 9. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.